相关实验视频
Updated: Jul 25, 2025

Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
通过TP53突变和缺氧介导的代谢改变调节的瘤微环境的表征
Kunpeng Luo1, Zhipeng Qian2, Yanan Jiang3
1The First Affiliated Hospital, Cardiovascular Lab of Big Data and lmaging Artificial Intelligence, Hengyang Medical School, University of South China Hengyang, Hunan, 421001, China; School of Computer, University of South China, Hengyang, Hunan, 421001, China; Department of Gastroenterology and Hepatology, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150081, China.
由TP53突变和缺氧驱动的代谢重编程影响瘤微环境和癌症进展. 这项研究开发了一种模型来预测预后和免疫疗法反应,确定特尼化物作为一种潜在的药物.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 瘤微环境 瘤微环境
背景情况:
- TP53突变和缺氧是癌症进展的关键驱动因素.
- 癌症中的代谢重编程和瘤微环境 (TME) 异质性仍然不完全理解.
研究的目的:
- 在各种癌症类型中全面分析代谢重编程模式和TME特征.
- 开发一种用于癌症预后和免疫治疗反应的预测模型.
- 为了确定癌症治疗的潜在治疗点.
主要方法:
- 利用来自32种癌症类型和免疫疗法队列的多组数据.
- 使用机器学习开发了代谢重编程评估模型 (拉索回归,神经网络,弹性网,生存SVM).
- 进行药物基因组学分析和体外检测以确定治疗药物.
主要成果:
- 在肝细胞癌 (HCC) 中确定了与TME特征相关的不同代谢亚型.
- 开发的代谢重编程模型的表现优于传统的预后指标.
- 代谢变化 (MA) 评分与瘤突变负担 (TMB),新抗原负载和同源重组缺陷 (HRD) 在癌症中正相关.
- 代谢重编程与膀癌中的免疫治疗敏感性有关.
结论:
- 由低氧和TP53突变驱动的代谢变化调节TME并影响癌症的进展.
- 建立了癌症预后和免疫治疗反应的预测模型.
- 提尼胺被确定为一种潜在的治疗药物,用于向癌症中的代谢变化.
相关概念视频
The Tumor Microenvironment
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Regulation of Angiogenesis and Blood Supply
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

